Sunday - June 21, 2026
European Medicines Agency Validates Marketing Authorisation Application for Jemperli Plus Chemotherapy for the Treatment of DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
April 26, 2023
LONDON, England, April 26 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 25, 2023:

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) validated the Company's Type II Variation for a potential new indication for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with a type of gynaecological cancer known as mismatch repair deficient (dMMR)/microsatellite instabilit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products